Figure 3.
SCFAs inhibited T2D-induced NF-κB activation and regulate GPR43-β-arrestin-2 signaling. (a) Western blotting revealed the expression of I-κBα, p-NF-κBp65, MCP-1, and IL-1β in T2D kidney tissue after SCFA treatment. (b, c) qRT-PCR of GPR43, GPR41, β-arrestin-2, and β-arrestin-1 in kidney tissue after SCFA treatment. (d) Western blotting-based assays for the expression of GPR43 and β-arrestin-2 in kidney tissue after SCFA treatment. (e) Immunohistochemistry- (400x) based assays for the expression of p-NF-κBp65, MCP-1, GPR43, and β-arrestin-2 after SCFA treatment. Ac: acetate; Pr: propionate; But: butyrate; ∗p < 0.05 compared with the NC group; #p < 0.05 compared with the T2D group; &p < 0.05 compared with the Ac or Pr group.